Frank-Peter Theil
Frank-Peter Theil has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Leslie A. Khawli
Department of Pathology, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA
4 shared publications - Charles Andrew Boswell
Genentech Research and Early Development, South San Francisco, California 94080, USA
3 shared publications Eduardo E. Mundo
3 shared publicationsPaul J. Fielder
3 shared publicationsCinthia V. Pastuskovas
2 shared publicationsDaniela Bumbaca
2 shared publications
Latest Publications
- Open Access
- 8 August 2016
- Published by Wiley in Journal of Immunology Research
- Vol. 2016, 1-9
Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins
Biologics have emerged as a powerful and diverse class of molecular and cell-based therapies that are capable of replacing enzymes, editing genomes, targeting tumors, and more. As this complex array of tools arises a distinct set of challenges is rarely encountered in the development of small molecule therapies. Biotherapeutics tend to be big, bulky, polar molecules comprised of protein and/or nucleic acids. Compared to their small molecule counterparts, they are fragile, labile, and heterogeneous. Their biodistribution is often limited by hydrophobic barriers which often restrict their administration to either intravenous or subcutaneous entry routes. Additionally, their potential for immunogenicity has proven to be a challenge to developing safe and reliably efficacious drugs. Our discussion will emphasize immunogenicity in the context of therapeutic proteins, a well-known class of biologics. We set out to describe what is known and unknown about the mechanisms underlying the interplay between antigenicity and immune response and their effect on the safety, efficacy, pharmacokinetics, and pharmacodynamics of these therapeutic agents.
- 8 August 2016
- Published by Wiley in Journal of Immunology Research
- Vol. 2016, 1-9
Open AccessUnraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins
Biologics have emerged as a powerful and diverse class of molecular and cell-based therapies that are capable of replacing enzymes, editing genomes, targeting tumors, and more. As this complex array of tools arises a distinct set of challenges is rarely encountered in the development of small molecule therapies. Biotherapeutics tend to be big, bulky, polar molecules comprised of protein and/or nucleic acids. Compared to their small molecule counterparts, they are fragile, labile, and heterogeneous. Their biodistribution is often limited by hydrophobic barriers which often restrict their administration to either intravenous or subcutaneous entry routes. Additionally, their potential for immunogenicity has proven to be a challenge to developing safe and reliably efficacious drugs. Our discussion will emphasize immunogenicity in the context of therapeutic proteins, a well-known class of biologics. We set out to describe what is known and unknown about the mechanisms underlying the interplay between antigenicity and immune response and their effect on the safety, efficacy, pharmacokinetics, and pharmacodynamics of these therapeutic agents.
- 1 July 2014
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 69 (2) , 226-233
New challenges and opportunities in nonclinical safety testing of biologics
- 1 July 2014
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 69 (2) , 226-233
New challenges and opportunities in nonclinical safety testing of biologics
- 1 February 2012
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 101 (2) , 509-515
Influence of the Compound Selection Process on the Performance of Human Clearance Prediction Methods
- 1 February 2012
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 101 (2) , 509-515
Influence of the Compound Selection Process on the Performance of Human Clearance Prediction Methods
- 12 August 2010
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 7 (5) , 1848-1857
Development and Evaluation of a Novel Method for Preclinical Measurement of Tissue Vascular Volume
Identification of clinically predictive models of disposition kinetics for antibody therapeutics is an ongoing pursuit in drug development. To encourage translation of drug candidates from early research to clinical trials, clinical diagnostic agents may be used to characterize antibody disposition in physiologically relevant preclinical models. TechneScan PYP was employed to measure tissue vascular volumes (V(v)) in healthy mice. Two methods of red blood cell (RBC) labeling were compared: a direct in vivo method that is analogous to a clinical blood pool imaging protocol, and an indirect method in which radiolabeled blood was transfused from donor mice into recipient mice. The indirect method gave higher precision in RBC labeling yields, lower V(v) values in most tissues, and lower (99m)Tc uptake in kidneys and bladder by single photon emission computed tomographic (SPECT) imaging relative to the direct method. Furthermore, the relative influence of each method on the calculated area under the first 7 days of the concentration-time curve (AUC(0-7)) of an IgG in nude mice was assessed using a physiologically based pharmacokinetic model. The model was sensitive to the source of V(v) values, whether obtained from the literature or measured by either method, when used to predict experimental AUC(0-7) values for radiolabeled trastuzumab in healthy murine tissues. In summary, a novel indirect method for preclinical determination of V(v) offered higher precision in RBC labeling efficiency and lower renal uptake of (99m)Tc than the direct method. In addition, these observations emphasize the importance of obtaining accurate physiological parameter values for modeling antibody uptake.
- 12 August 2010
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 7 (5) , 1848-1857
Development and Evaluation of a Novel Method for Preclinical Measurement of Tissue Vascular Volume
Identification of clinically predictive models of disposition kinetics for antibody therapeutics is an ongoing pursuit in drug development. To encourage translation of drug candidates from early research to clinical trials, clinical diagnostic agents may be used to characterize antibody disposition in physiologically relevant preclinical models. TechneScan PYP was employed to measure tissue vascular volumes (V(v)) in healthy mice. Two methods of red blood cell (RBC) labeling were compared: a direct in vivo method that is analogous to a clinical blood pool imaging protocol, and an indirect method in which radiolabeled blood was transfused from donor mice into recipient mice. The indirect method gave higher precision in RBC labeling yields, lower V(v) values in most tissues, and lower (99m)Tc uptake in kidneys and bladder by single photon emission computed tomographic (SPECT) imaging relative to the direct method. Furthermore, the relative influence of each method on the calculated area under the first 7 days of the concentration-time curve (AUC(0-7)) of an IgG in nude mice was assessed using a physiologically based pharmacokinetic model. The model was sensitive to the source of V(v) values, whether obtained from the literature or measured by either method, when used to predict experimental AUC(0-7) values for radiolabeled trastuzumab in healthy murine tissues. In summary, a novel indirect method for preclinical determination of V(v) offered higher precision in RBC labeling efficiency and lower renal uptake of (99m)Tc than the direct method. In addition, these observations emphasize the importance of obtaining accurate physiological parameter values for modeling antibody uptake.